Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals

This study describes humoral and cell mediated immune (CMI) responses detected in cyclophosphamide (CY) treated animals who were vaccinated with Candida albicans ribosomes and were protected against systemic candidiasis (previous study). Mice treated with CY and vaccinated with C. albicans ribosomes...

Full description

Saved in:
Bibliographic Details
Published in:Mycopathologia (1975) 1985-02, Vol.89 (2), p.113-118
Main Authors: SEGAL, E, SANDOVSKY-LOSILA, H, NUSSBAUM, S
Format: Article
Language:English
Subjects:
Animals
Antibodies, Fungal - analysis
Biological and medical sciences
Candida albicans
Candida albicans - immunology
Cyclophosphamide - pharmacology
Enzyme-Linked Immunosorbent Assay
Experimental mycoses and models
Female
Infectious diseases
Lymphocyte Activation
Medical sciences
Mice
Mice, Inbred BALB C
Mycoses
Ribosomes - immunology
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study describes humoral and cell mediated immune (CMI) responses detected in cyclophosphamide (CY) treated animals who were vaccinated with Candida albicans ribosomes and were protected against systemic candidiasis (previous study). Mice treated with CY and vaccinated with C. albicans ribosomes revealed CMI responses towards the ribosomes as measured in vivo by the foot pad swelling test and in vitro by the lymphocyte transformation assay. Both reactions were higher in CY treated and ribosome vaccinated mice than in controls (mice that were only vaccinated). Humoral immune responses were measured by the enzyme linked immunosorbent assay (ELISA). Anti ribosomal antibody titer contrary to the CMI responses was lower in CY treated animals than in non treated controls. These data point to a possible explanation of the mechanisms underlying the ribosomal vaccinations in CY treated hosts, and show the potential of such vaccinations in compromised individuals.
ISSN:0301-486X
1573-0832
DOI:10.1007/BF00431479